

Evaluation Report for Category L, Subcategory 1.1 Application

Application Number: 2019-6059
Application: Submissions Subject to Protection of Proprietary Interests in Pesticide Data Policy/ Data Compensation Assessment
Product: Sharda Clomazone Technical
Registration Number: #####
Active ingredient (a.i.): Clomazone
PMRA Document Number 3178079

Purpose of Application

The purpose of this application was to register Sharda Clomazone Technical, based on a precedent.

Chemistry Assessment

Common Name: Clomazone
IUPAC* Chemical Name: 2-(2-chlorobenzyl)-4,4-dimethylisoxazolidin-3-one
CAS† Chemical Name: 2-[(2-chlorophenyl)methyl]-4,4-dimethyl-3-isoxazolidinone

* International Union of Pure and Applied Chemistry

† Chemical Abstracts Service

Sharda Clomazone Technical has the following properties:

| Property | Result |
|---------------------------------------|--------------------------------------|
| Colour and physical state | White powder |
| Nominal concentration | 99.9 % |
| Odour | characteristic odour |
| Density | 1.2339 g/mL |
| Vapour pressure | 9.42 x 10 ⁻² Pa (at 25°C) |
| pH | 5.1 (1% solution in water) |
| Solubility in water | 1.28 g/L (20°C) |
| n-Octanol/water partition coefficient | log Kow = 2.72 |

The required chemistry data for Sharda Clomazone Technical have been provided, reviewed, and

found to be acceptable.

Health, Environmental and Value Assessments

Health, environmental and value assessments were not required for this application.

Conclusion

The Pest Management Regulatory Agency has completed an assessment of the information provide and has found it sufficient to support the registration of Sharda Clomazone Technical.

References

| PMRA Document Number | References |
|----------------------|--|
| 3047731 | 2019, Clomazone manufacturing process and impurities formation description, DACO: 2.11.1,2.11.2,2.11.3,2.11.4 CBI |
| 3047735 | 2017, Clomazone Technical: [CBI removed] Screening for Impurities Content in Five Batch Samples, DACO: 2.13.1,2.13.2,2.13.4 CBI |
| 3047733 | 2017, Clomazone Technical: Complete Analysis of Five Batch Samples, DACO: 2.13.3 CBI |
| 3047732 | 2017, Clomazone Technical: Validation of the Analytical Method for the Determination of the Active Ingredient Content, DACO: 2.13.1,2.13.2 |
| 3047737 | 2017, Clomazone Technical: Spectroscopic Characterisation, DACO: 2.14.12 |
| 3047736 | 2017, Clomazone Technical: Determination of the Physico-chemical Properties, DACO: 2.14.1, 2.14.10, 2.14.11, 2.14.12, 2.14.13, 2.14.15, 2.14.2, 2.14.3, 2.14.4, 2.14.5, 2.14.6, 2.14.7, 2.14.8, 2.14.9, 2.16 |
| 3047739 | 2017, Clomazone Technical: Determination of the Accelerated Storage Stability and Corrosion Characteristics, DACO: 2.14.14 |
| 3047734 | 2019, Waiver for Analysis of [CBI removed] as Impurity, DACO: 2.13.4 CBI |
| 3060575 | 2019, Declaration of Clomazone Technical Source for 5-batch analysis, DACO: 2.13.3 CBI |

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health Canada, 2021

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.